Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Altimmune, Inc. (Nasdaq: ALT) generates a steady flow of news as a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver, metabolic and cardiometabolic diseases. Most company updates center on its lead investigational medicine, pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), alcohol-associated liver disease (ALD) and obesity.
News coverage of ALT frequently highlights clinical trial milestones. Altimmune issues detailed press releases on the IMPACT Phase 2b trial in MASH, including 24-week and 48-week topline data, changes in non-invasive tests of fibrosis and hepatic inflammation, and AI-based digital pathology analyses of liver biopsies. Additional updates describe progress in the RECLAIM Phase 2 trial in AUD and the RESTORE Phase 2 trial in ALD, including enrollment status and expected timelines for topline results.
Investors and followers of ALT stock also see regulatory and scientific news, such as Fast Track designations for pemvidutide in MASH and AUD, Breakthrough Therapy Designation for MASH, and publication of IMPACT trial data in peer-reviewed journals. Presentations at major medical meetings, including late-breaking oral and poster sessions at The Liver Meeting hosted by the American Association for the Study of Liver Diseases (AASLD), are common subjects of company announcements.
Altimmune’s news flow further includes corporate and financial updates. These range from quarterly financial results and business updates to CEO succession plans, executive appointments, term loan amendments and at-the-market equity offering arrangements disclosed in SEC filings and companion press releases. For anyone tracking ALT, this news page brings together clinical, regulatory, scientific and corporate developments in one place, making it easier to follow how Altimmune’s programs and capital strategy evolve over time.
Altimmune, Inc. (Nasdaq: ALT) announced a planned underwritten public offering of common stock, which may include pre-funded warrants for certain investors. The underwriters will have an option to purchase an additional 15% of shares. Proceeds will be used for general corporate purposes, including scaling up manufacturing for its COVID vaccine candidate AdCOVID and advancing clinical trials for ALT-801, targeting non-alcoholic steatohepatitis. The offering is subject to market conditions and is being managed by Jefferies, Evercore ISI, and Piper Sandler.
Altimmune, Inc. (Nasdaq: ALT) announced promising results from preclinical studies of its intranasal COVID-19 vaccine candidate, AdCOVID. Conducted with UAB, the studies indicated strong serum neutralizing activity and mucosal immunity. AdCOVID demonstrated significant antibodies in mice, reaching serum IgG concentrations over 800 µg/mL within 14 days. The vaccine will progress to Phase 1 trials in Q4 2020. Notably, its intranasal delivery could enhance rapid administration and distribution without cold-chain requirements.
Summary not available.
Altimmune, Inc. (Nasdaq: ALT) has received FDA clearance for its Investigational New Drug (IND) application to proceed with a Phase 2 trial of HepTcell, an immunotherapeutic aimed at treating chronic hepatitis B. The company is also filing trial applications in multiple countries, including Canada and the UK. Scheduled for Q4 initiation, this trial includes 80 adult subjects and focuses on breaking immune tolerance to achieve a functional cure for HBV. HepTcell shows potential as a key component in future anti-HBV treatment regimens.
Altimmune received FDA clearance for its IND application to begin a Phase 1/2 trial of T-COVID, targeting early SARS-CoV-2 infections. The trial, enrolling around 100 patients, aims to assess the drug's efficacy in preventing disease progression in non-hospitalized patients diagnosed within 48 hours. Scheduled to start in June 2020, results are expected by Q4 2020. T-COVID leverages the company's RD-Ad5 adenoviral vector technology, and offers a novel approach by being administered intranasally, potentially avoiding hospitalization and requiring no refrigeration for distribution.
Altimmune, Inc. (Nasdaq: ALT) reported financial results for Q1 2020, highlighting revenue of $2.2 million down from $3 million year-over-year due to reduced contract billings. R&D expenses surged to $7.2 million compared to $3.2 million in the prior year, driven by IND-enabling studies. The net loss was $3.9 million or ($0.26) per share. Notably, the company commenced preclinical testing of COVID-19 vaccine AdCOVID and plans to launch clinical trials for NasoShield and ALT-801 later in the year, aiming for a data-rich 2020.
Altimmune, a clinical-stage biopharmaceutical company, announced the appointment of Diane Jorkasky, M.D. to its Board of Directors, expanding the board to eight members. Dr. Jorkasky brings extensive experience in drug development across various therapeutic areas. CEO Vipin K. Garg expressed excitement over her contributions to Altimmune's ongoing liver disease and vaccine programs. Dr. Jorkasky emphasized the company's potential impact on public health. Her background includes leadership roles in major pharmaceutical firms, underscoring the breadth of knowledge she brings to the team.